Event 26 Aug - 29 Aug 2022
ESC Congress 2022
Cereno will present the abstract “CS014 is a novel HDAC inhibitor regulating platelet activity, fibrinolysis and clot stability for prevention...
Investors
Phase II company positioned for growth
Cereno Scientific is well-positioned for strong growth in an attractive cardiovascular and rare diseases market with a diversified portfolio of clinical and preclinical candidates.
A clinical phase II study is planned with CS1 for the treatment of the rare disease pulmonary arterial hypertension (PAH).
Pipeline
Therapeutics in common and rare cardiovascular disease
Cereno has a project portfolio targeting common and rare cardiovascular diseases. The aim is to develop treatments that can improve the life for affected patients. The portfolio comprises a Phase II program and two preclinical programs.
Therapeutic focus
Better efficacy and fewer side effects in focus
Cardiovascular disease is the number 1 cause of death globally, killing nearly twice as many people as cancer. Cereno has an extensive experience in cardiovascular diseases and works toward the aim of developing novel, better treatments to improve the health of cardiovascular patients, both in common and rare diseases.